Potentiation of crizotinib activity by fasting cycles in an ALK+ lung cancer model (original) (raw)

Journal of Clinical Oncology, 2014

Abstract

e13511 Background: The ALK inhibitor crizotinib is the standard of care of patients with ALK+, advanced NSCLC. However, its clinical benefit is limited by the development of resistance. Cycles of f...

Franco Patrone hasn't uploaded this paper.

Let Franco know you want this paper to be uploaded.

Ask for this paper to be uploaded.